BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that four abstracts highlighting data from the Company's adoptive cell-based therapeutic programs have been accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego. The research, conducted at The University of Texas MD Anderson Cancer Center and Intrexon Corporation (NYSE:XON) demonstrates, among other results, that T cells can be quickly produced with the Sleeping Beauty system and that this non-viral approach to gene therapy can be harnessed to generate chimeric antigen receptor (CAR) and T-cell receptor (TCR) expressing effector cells. "This suite of nonclinical data underscores the technology underlying our adoptive cell-based programs, including the potential for the Sleeping Beauty platform to improve the manufacture of genetically modified T cells and our ability to redirect T-cell specificity to blood cancers and solid tumors using CARs and TCRs," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "This research advances our plans to rapidly and cost-effectively deliver engineered T cells, and we look forward to seeing it translate into clinical programs." Details for ASH presentations are as follows:Title: Very Rapid Production of CAR +T Cells upon Non-viral Gene Transfer using the Sleeping Beauty System Session Title: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation Date and Time: Sunday, December 4, 2016, 6:00 - 8:00 p.m. PT Publication ID: 2807 Location: San Diego Convention Center, Hall GH Title: Personalization of T-cell Therapy using a High-throughput Platform to Identify Tumor-specific T-cell Receptors Session Title: 703. Adoptive Immunotherapy: Poster II Date and Time: Sunday, December 4, 2016, 6:00 - 8:00 p.m. PT Publication ID: 3359 Location: San Diego Convention Center, Hall GH Title: Combination Immunotherapy with NY-ESO-1 Specific CAR +T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect Session Title: 703. Adoptive Immunotherapy: Poster II Date and Time: Sunday, December 4, 2016, 6:00 - 8:00 p.m. PT Publication ID: 3366 Location: San Diego Convention Center, Hall GH Title: Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33 Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Date and Time: Monday, December 5, 2016, 6:00 - 8:00 p.m. PT Publication ID: 4058 Location: San Diego Convention Center, Hall GH About ZIOPHARM Oncology, Inc.: ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.